MRP of 3 Anti-cancer drugs to come down

     Raipur, October 29, 2024: National Pharmaceutical Pricing Authority (NPPA) has directed the concerned manufacturers to reduce the maximum retail price (MRP) on three anti-cancer drugs, Trastuzumab, Osimertinib and Durvalumab. 

     This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty, official sources said.

     The Department of Revenue, Union Ministry of Finance issued the Notification 30/2024 dated 23.07.2024 reducing the custom duty to nil on these three anti-cancer drugs.

     Further, the Department of Revenue has issued notification no. 05/2024 dated 08.10.2024 notifying the reduction in GST Rates from 12 per cent to 5 per cent with effect from 10.10.2024 on these three drugs.

     Accordingly, there should be a reduction in MRP of these drugs in the market and benefits of reduced taxes and duties should be passed on to the consumers, they said.

     Hence, NPPA vide O.M. dated 28.10.2024 has directed all the manufacturers of above-mentioned drugs to reduce their MRP. The manufacturers are required to issue a price list or supplementary price list to the dealers, State Drugs Controllers and the Government indicating changes and to submit information regarding price change to NPPA through Form-II/ Form V, the official sources added.